ArkAb SAS of Limoges at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option


Bât EFS 98, rue Charles le Gendre, 87000 Limoges
Telephone +33 5 55439777

This company is co-exhibitor of
Business France EPIC

Hall map

MEDICA 2019 hall map (Hall 3): stand G80

Fairground map

MEDICA 2019 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing

Our products

Product category: Immuno assay testing


Chimeric human/mouse monoclonal IgM targeting gangliosides GM1.

Gangliosides are glycolipids which mainly take part in the recognition of molecules among cellular membranes. 

The accumulation of gangliosides is often observed among patients with a lysosomic disease. Therefore, antibodies targeting gangliosides are a relevant marker to diagnose this kind of disease. 

More Less

Product category: Immuno assay testing


Chimeric human/mouse monoclonal IgA1 directed against gliadin.
Associated with celiac disease.
Available in antibody culture supernatant or purified forms.

More Less

Product category: Immuno assay testing


Chimeric human/mouse monoclonal IgM targeting Toxoplasma gondii.

ToRCH parameters through SERION Immunologics

More Less

Product category: Immuno assay testing


Monoclonal human/mouse chimeric IgA directed against human IgE heavy chain

More Less

About us

Company details

ArkAb is B Cell Design subsidiary focused on the in vitro diagnostic market. ArkAb offers to IVD companies a reliable, reproducible and secured source of chimeric human antibodies for several purposes:

  • Calibrators, positive controls and quality controls for in vitro diagnostic immunoassays to replace human disease state plasma
  • Immunocapture antibodies to replace mice antibodies which trigger false positive or false negative answers due to HAMA antibodies.
  • Research reagents (development or renewal of diagnostic kits, improvement of the products portfolio…)
B Cell Design develops a new mucosal immunotherapy approach for generating a large number of drug and vaccine candidates in infectious field and oncology. 
This leads to develop two groundbreaking drug candidates:

  • A vaccine candidate in infectious diseases field: a worldwide patented HIV vaccine (A new non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection – Europe Patent 14305174.6) to prevent or even cure HIV infections. Preliminary studies showed that this approach elicits an efficient local immune response, neutralizing HIV infection of human cells.
  • A drug candidate in oncology field (colorectal cancer) for immunotherapy, radioimmunotherapy applications or medical imaging.
For more information about B Cell Design, please visit!

More Less